Genetic factors in graft fatty liver after living-donor liver transplant
Official title: Influence of Donor and Recipient PNPLA3 and MBOAT7 Gene Polymorphisms on Graft Liver Steatosis After Living Donor Liver Transplant for Metabolic Dysfunction-associated Steatohepatitis (MASH) Related Cirrhosis
Run by Institute of Liver and Biliary Sciences, India · NCT07685353 · Data updated 2026-11-12
This study will see if donor and recipient genetic variants, especially PNPLA3 and MBOAT7, are linked to fat buildup in the transplanted liver among adults who had living-donor liver transplants for MAFLD-related cirrhosis.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Institute of Liver and Biliary Sciences, India Academic / other |
| Locations | 1 site (New Delhi) |
| Status | Recruiting |
| Started | July 7, 2026 |
| Main results expected | October 31, 2026 |
| Study ends | October 31, 2026 |
| Registry record updated | July 21, 2026 |
| Trial ID | NCT07685353 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults who underwent living-donor liver transplantation for MAFLD-related chronic liver disease at ILBS at least 3 years ago, along with their donors.
✕Probably not a fit
Patients outside the LDLT context or those transplanted for non-MASH etiologies may not derive insights from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational study analyzing how recipient and donor genetics may influence fat accumulation in the liver graft after living-donor transplantation for MAFLD-related chronic liver disease. It focuses on PNPLA3 and MBOAT7 variants and considers environmental factors to understand the polygenic nature of graft steatosis. The study builds on evidence of heritability of hepatic fat content and seeks data from a high-volume center in New Delhi. No interventions are being tested; researchers will examine existing transplant recipients and their donors to identify associations between genotypes and graft outcomes. The results could clarify whether genetic profiles help predict MAFLD recurrence in the transplanted liver.
Why it matters
Potential benefit: If successful, findings could help identify patients at higher risk of graft steatosis and inform personalized post-transplant management.
How similar studies have gone: Prior research links PNPLA3 and MBOAT7 variants to MAFLD, but few have studied donor–recipient genetics in living-donor transplants, making this approach relatively novel in this setting.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * All LDLT recipients with MASH related CLD and their donors who underwent their surgery at ILBS at least 3 years prior to the onset of this study. Exclusion Criteria: * Pediatric (\<18 years) * Transplants for ALF/ ACLF
Where it's running
-
Institute of Liver and Biliary Sciences
New Delhi, India Recruiting
Study contacts
- Study coordinator: Naren Mandalapu, MS
- Email: bearebel69@gmail.com
- Phone: +918096006447
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Magnetic Resonance Cholangiopancreatography to help living liver donors and their recipients
This study tests whether preoperative MRCP imaging can help select living liver donors and reduce biliary complications in recipients.
-
How liver transplant affects sexual life and function
This project will try to see if sexual function improves after liver transplant in married men with decompensated chronic liver disease and in men who already have a stable liver transplant.
-
Gathering data on hepatomiR for liver disease outcomes
This study is trying to see how a new test for liver disease can help doctors understand and predict serious problems in patients with chronic liver issues.
-
Creating biological models to study liver diseases and tumors
This study is trying to create new models to better understand liver diseases and tumors so that we can find better treatments for people suffering from these conditions.
-
Predicting liver deterioration and death in people with cirrhosis
This project will try to identify clinical signs and lab or imaging markers that predict worsening, acute-on-chronic liver failure (ACLF), or death in adults with cirrhosis treated at Singapore hospitals.
-
Microplastics in the liver of people with cirrhosis and portal hypertension
This study tests whether microplastics and nanoparticles accumulate in the livers of adults with cirrhosis and portal hypertension who are undergoing surgery or transplant, to understand where they go and what form they take.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.